DESTINY-Breast11 -

Name: DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Uploaded: 2026-06-03T04:00:00+00:00
Duration: 4 min 8 s
Description: In this video brief, Dr. Sara Hurvitz reviews key findings from DESTINY-Breast11 and their implications for patient care and clinical decision-making.

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Project Oncology®
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Brian P. McDonough, MD, FAAFP; Andrew E. Hendifar, MD
- Brian P. McDonough, MD, FAAFP
- Andrew E. Hendifar, MD
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Project Oncology®
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Charles Turck, PharmD, BCPS, BCCCP; Rohit Thummalapalli, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Rohit Thummalapalli, MD
Key Differences in Pulmonary and Extrapulmonary NEC Management
Key Differences in Pulmonary and Extrapulmonary NEC Management
Project Oncology®
Key Differences in Pulmonary and Extrapulmonary NEC Management
Alexandria May, PharmD, BCPS; Lowell B. Anthony, MD, FACP
- Alexandria May, PharmD, BCPS
- Lowell B. Anthony, MD, FACP
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
- Tiffany Traina, MD, FASCO